Avivagen Announces Presentation at Bloom Burton & Co. Conference on May 4, 2015

OTTAWA, ON / ACCESSWIRE / May 1, 2015 / Avivagen Inc. (TSX VENTURE: VIV, PINKSHEETS: CHEXF), a life sciences company that develops and delivers products that support and enhance the health of livestock, pets and people, announces that it will be presenting at the Bloom Burton & Co. Healthcare Investment Conference on May 4th, 2015.

The conference’s creator, Bloom Burton & Co., is a Toronto-based investment bank that is exclusively focused on the healthcare industry. Its services include sourcing capital, enabling monetization, conducting research and direct investing. The conference will host a chosen list of Canada’s premier publicly-traded, venture-backed private and pre-venture companies in the healthcare industry and be attended by Canadian, U.S., and international investors. Further information about Bloom Burton & Co. is available at www.bloomburton.com.

The conference will be held at the Sheraton Centre Toronto Hotel and will consist of presentations by invited companies and meetings between their management and investors. Avivagen will speak at 3:30 PM on Monday, May 4th and its presentation is now posted to the company website at www.avivagen.com.

Cameron Groome, CEO of Avivagen, commented about the Company’s attendance, “We’re pleased to be invited to present at this year’s event: We consider selection by the independent conference committee of the only Canadian investment bank solely dedicated to healthcare to be an indication of the progress of our business.”

Avivagen management believes attendance at such investor conferences provides a forum to communicate with current and prospective shareholders. Effective shareholder communications can help to optimize the trading liquidity of Avivagen shares and to ensure their efficient valuation by capital markets.

About Avivagen Inc.

Avivagen Inc. is a publicly-listed life sciences company trading on the TSX Venture Exchange under the ticker symbol “VIV” and on OTC Pink as “CHEXF.” The Company’s goal is to develop and deliver scientifically-proven solutions that benefit companion and production animals by employing natural mechanisms for maintaining good health. Target markets include Livestock Productivity and Pet Wellness.

Avivagen is based in partnership facilities of the National Research Council of Canada (NRC) – in Ottawa, Ontario and Charlottetown, Prince Edward Island. For more information, visit www.avivagen.com.

About OxC-beta(TM) fully oxidized beta-carotene (“OxC-beta”)

Avivagen’s proprietary and patent-protected technology is based on its discoveries concerning carotenoid antioxidants. The novel natural compounds discovered by Avivagen support the body’s own systems to maintain and enhance health, by supporting immune function and calming excess inflammation. Avivagen’s commercial-stage application of its technology is fully-oxidized beta-carotene. Fully oxidized beta-carotene compounds occur naturally as carotenoid oxidation products in vegetation, but in minute amounts. They have been developed to support companion animal health and for use in the global food animal market.

Research results indicate OxC-beta supports innate immune function and reduces late-stage inflammation, which can help maintain good health. In pets, OxC-beta supports overall vitality and energy, mobility and joint function, and skin, coat and gut health. Results observed in food animals have included healthier growth, more efficient utilization of feed and decreased morbidity. In food animals, it is intended that use of OxC-beta avoids the feeding of antibiotics. Avivagen’s commercial products are OxC-beta(TM) Livestock (Kingdom of Thailand), Vivamune(TM) Vital Health3 Chews (United States) and Oximunol(TM) Chewable Tablets (United States).

About OxC-beta(TM) Livestock

OxC-beta(TM) Livestock is available as a 10% pre-mix sold in 1.0 or 5.0 Kg quantities for parts-per-million addition to animal feeds, in accordance with Avivagen or producer-developed protocols. In past studies, OxC-beta(TM) Livestock has been shown to support health or growth in species such as chicken, pigs, cattle and fish. OxC-beta(TM) Livestock is currently available for commercial sale in the Kingdom of Thailand.

About Vivamune(TM) Vital Health3 Chews – For dogs and cats

Vivamune(TM) Vital Health3 Chews, containing Avivagen’s proprietary active ingredients, are scientifically-formulated chews for dogs and cats. Vivamune(TM) Vital Health3 Chews work with a pet’s own immune system to help it maintain overall health and well-being. They are sold in re-sealable packages of 30 chews and are currently available in the United States by ordering on-line at www.vivamunehealth.com.

About Oximunol(TM) Chewable Tablets – For dogs

Oximunol(TM) Chewable Tablets are scientifically-formulated chewable tablets that contain Avivagen’s proprietary, patented active ingredient OxC-beta(TM). OxC-beta(TM) has been shown to stimulate innate cellular immunity and may thereby help to maintain overall health and well-being. Oximunol(TM) Chewable Tablets were distributed by a multinational animal health company in the United States and Avivagen is now working to identify a new partner through which to distribute to veterinarians for dogs of all ages.

Permanent Non-Surgical Sterilization of Female Mammals

Avivagen has optioned worldwide exclusive rights to a technology for the permanent and non-surgical sterilization of female mammals. Proof-of-concept work is ongoing to demonstrate whether the technology appears to be safe and effective. It is expected that a patent covering World Trade Organization countries will be pursued and further information will be disclosed when a patent application is published or as otherwise deemed prudent or required.

Forward Looking Statements

This news release includes certain forward-looking statements that are based upon the current expectations of management. Forward-looking statements involve risks and uncertainties associated with the business of Avivagen Inc. and the environment in which the business operates. Any statements contained herein that are not statements of historical facts may be deemed to be forward-looking, including those identified by the expressions “aim”, “anticipate”, “appear,” “believe,” “consider,” “could,” “estimate,” “expect,” “if,” “intend,” “goal,” “hope,” “likely,” “may,” “plan,” “possibly,” “potentially,” “seem,” “should,” “whether,” “will,” “would” and similar expressions. Statements about uses of the technologies described in this news release, including their importance to animal or human health, their novelty, safety, efficacy or affordability, comments about the conference sponsors or presenting companies, management’s believes about the meaning of being invited, what attendance at the conference may accomplish and about shareholder communications, are all forward looking statements. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Such Avivagen risks and uncertainties include, but are not limited to, the following: its ability to continue as a going concern; the results of ongoing or future trials may not be positive or sufficiently positive; even if the results of trials are positive, there is no guarantee that its products will be commercially successful or that requisite regulatory approvals will be obtained; the timing and results of trials may be delayed or may not be completed at all; and intellectual property rights may prove inadequate to protect its inventions. Accordingly, readers should not place undue reliance on forward-looking statements. Except as required by law, Avivagen assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those reflected in the forward-looking statements.

Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.

For more information:
Avivagen Inc.

Cameron Groome, CEO & President
100 Sussex Drive
Ottawa, Ontario
Canada K1A 0R6
Head Office Phone: 613-949-8164
Website: www.avivagen.com

SOURCE: Avivagen Inc.

ReleaseID: 428407